Paper39367409
Pharmacological targeting of P300/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcoma.
Wei E and 9 others. Mol Cancer, 2024. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. Pharmacological targeting of P300/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcoma. Papers, record 39367409. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39367409
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pharmacological targeting of P300/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcoma.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cellular Senescence | Major topic |
| Oncogene Proteins, Fusion | Major topic |
| p300-CBP Transcription Factors | Major topic |
| Proto-Oncogene Protein c-fli-1 | Major topic |
| RNA-Binding Protein EWS | Major topic |
| Sarcoma, Ewing | Major topic |
| Humans | |
| Cell Line, Tumor | |
| Gene Expression Regulation, Neoplastic | |
| Mesenchymal Stem Cells | |
| Signal Transduction | |
| E1A-Associated p300 Protein |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| HT9425-23-1-0456 | Department of Defense | PubMed |
Source PubMed
References70
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28710342 | Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. | Oncologist | 2017 | https://conductscience.org/library/papers/28710342 | PubMed |
| 2 | 36117234 | Pharmacological targeting of CBP/p300 drives a redox/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cells. | Cancer Gene Ther | 2023 | https://conductscience.org/library/papers/36117234 | PubMed |
| 3 | 25453903 | EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. | Cancer Cell | 2014 | https://conductscience.org/library/papers/25453903 | PubMed |
| 4 | 34642317 | Inactivation of the CIC-DUX4 oncogene through P300/CBP inhibition, a therapeutic approach for CIC-DUX4 sarcoma. | Oncogenesis | 2021 | https://conductscience.org/library/papers/34642317 | PubMed |
| 5 | 37848888 | Engineering siRNA therapeutics: challenges and strategies. | J Nanobiotechnology | 2023 | https://conductscience.org/library/papers/37848888 | PubMed |
| 6 | 32371576 | Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. | Mol Cancer Ther | 2020 | https://conductscience.org/library/papers/32371576 | PubMed |
| 7 | 35252191 | Why Senescent Cells Are Resistant to Apoptosis: An Insight for Senolytic Development. | Front Cell Dev Biol | 2022 | https://conductscience.org/library/papers/35252191 | PubMed |
| 8 | 33497548 | Ewing's Sarcoma. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33497548 | PubMed |
| 9 | 16921403 | Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. | Nat Rev Mol Cell Biol | 2006 | https://conductscience.org/library/papers/16921403 | PubMed |
| 10 | 35950293 | A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. | Cancer Med | 2023 | https://conductscience.org/library/papers/35950293 | PubMed |
| 11 | 27109631 | Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma. | Mol Ther | 2016 | https://conductscience.org/library/papers/27109631 | PubMed |
| 12 | 11591713 | Dual role of p300 in the regulation of p53 stability. | J Biol Chem | 2001 | https://conductscience.org/library/papers/11591713 | PubMed |
| 13 | 12086853 | The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. | Cancer Cell | 2002 | https://conductscience.org/library/papers/12086853 | PubMed |
| 14 | 20547982 | Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20547982 | PubMed |
| 15 | 35836809 | Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents. | Theranostics | 2022 | https://conductscience.org/library/papers/35836809 | PubMed |
| 16 | 33850273 | P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. | Acta Pharmacol Sin | 2022 | https://conductscience.org/library/papers/33850273 | PubMed |
| 17 | 29382926 | Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. | Oncogene | 2018 | https://conductscience.org/library/papers/29382926 | PubMed |
| 18 | 26951377 | DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes. | Nucleic Acids Res | 2016 | https://conductscience.org/library/papers/26951377 | PubMed |
| 19 | 20808728 | Regularization Paths for Generalized Linear Models via Coordinate Descent. | J Stat Softw | 2010 | https://conductscience.org/library/papers/20808728 | PubMed |
| 20 | 32366905 | Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma. | Oncogene | 2020 | https://conductscience.org/library/papers/32366905 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42643391 | Aging-associated immune and stromal programs mark interferon- and remodeling-linked spatial contexts in psoriatic skin. | Front Immunol | 2026 | https://conductscience.org/library/papers/42643391 | PubMed |
| 42464641 | From cell to disease: Regulatory networks and mechanisms of super‑enhancers in aging (Review). | Mol Med Rep | 2026 | https://conductscience.org/library/papers/42464641 | PubMed |
| 41957177 | Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41957177 | PubMed |
| 41889820 | An epigenetic bifunctional that toggles between transactivation and repression. | bioRxiv | 2026 | https://conductscience.org/library/papers/41889820 | PubMed |
| 41676338 | RNA-based therapies for colorectal cancer: targeting the β-catenin pathway via microbiota -modulated miRNAs. | Front Mol Biosci | 2025 | https://conductscience.org/library/papers/41676338 | PubMed |
| 41659547 | BAF complex-independent gene activation by SS18::SSX. | bioRxiv | 2026 | https://conductscience.org/library/papers/41659547 | PubMed |
| 41594575 | Heterogeneous Folding Intermediates Govern the Conformational Pathway of the RNA Recognition Motif Domain of the Ewing Sarcoma Protein. | Biomolecules | 2025 | https://conductscience.org/library/papers/41594575 | PubMed |
| 41299516 | Modeling CIC::DUX4 sarcoma reveals oncogene-mediated MHCI-dependent immune evasion. | Mol Cancer | 2025 | https://conductscience.org/library/papers/41299516 | PubMed |
| 41240117 | Clinical characteristics and target exploration via scRNA-seq and high-throughput drug screening of FOXO1 fusion positive rhabdomyosarcoma. | Pediatr Surg Int | 2025 | https://conductscience.org/library/papers/41240117 | PubMed |
| 41228232 | Masters of Gene Expression: Transcription Factors in Pediatric Cancers. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228232 | PubMed |
| 40429954 | The Double Life of microRNAs in Bone Sarcomas: Oncogenic Drivers and Tumor Suppressors. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40429954 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CREBBP | 1387 | PubTator's text mining | https://conductscience.org/library/genes/1387 | NCBI Gene |
| EP300 | 2033 | PubTator's text mining | https://conductscience.org/library/genes/2033 | NCBI Gene |
| EWSR1 | 2130 | PubTator's text mining | https://conductscience.org/library/genes/2130 | NCBI Gene |
| LMNB1 | 4001 | PubTator's text mining | https://conductscience.org/library/genes/4001 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39367409
GET https://conductscience.org/api/papers/v1/39367409/references?page=2